| Identification | More | [Name]
4-Hydroxy-2-oxopyrrolidine-N-acetamide | [CAS]
62613-82-5 | [Synonyms]
4-HYDROXY-2-OXOPYRROLIDINE-N-ACETAMIDE
OXIRACETAM
4-hydroxy-2-oxo-1-pyrrolidineacetamid
4-hydroxy-2-oxo-1-pyrrolidineacetamide
4-hydroxypiracetam
ct-848
hydroxypiracetam
isf2522
Oxriacetam
2-(4-HYDROXY-PYRROLIDINO-2-ON-1-YL)ETHYL ACETATE
4-1-lydroxypiracetan
Neuractiv
Neurome
2-(4-Hydroxy-2-oxopyrrolidin-1-yl)acetamide | [EINECS(EC#)]
636-370-0 | [Molecular Formula]
C6H10N2O3 | [MDL Number]
MFCD00242951 | [Molecular Weight]
158.16 | [MOL File]
62613-82-5.mol |
| Chemical Properties | Back Directory | [Melting point ]
165-168 °C | [Boiling point ]
494.6±40.0 °C(Predicted) | [density ]
1.416 | [storage temp. ]
2-8°C
| [solubility ]
DMSO (Slightly, Heated), Methanol (Slightly, Heated) | [form ]
Solid | [pka]
13.76±0.20(Predicted) | [color ]
White to Off-White | [Merck ]
14,6942 | [InChI]
InChI=1S/C6H10N2O3/c7-5(10)3-8-2-4(9)1-6(8)11/h4,9H,1-3H2,(H2,7,10) | [InChIKey]
IHLAQQPQKRMGSS-UHFFFAOYSA-N | [SMILES]
N1(CC(N)=O)CC(O)CC1=O | [CAS DataBase Reference]
62613-82-5(CAS DataBase Reference) |
| Safety Data | Back Directory | [Hazard Codes ]
Xi | [Risk Statements ]
R36/38:Irritating to eyes and skin . | [Safety Statements ]
S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice .
S36:Wear suitable protective clothing . | [WGK Germany ]
3
| [RTECS ]
UX9656638
| [HS Code ]
2933.79.8500 |
| Questions And Answer | Back Directory | [Indications and Usage]
Oxiracetam is a more potent derivative of the nootropic drug piracetam. They were developed in 1974 by the Italian company ICF and went on sale in 1987. Oxiracetam is a Piracetam derivative and excites the central nervous system, promotes brain metabolism, significantly increases and promotes memory retention, and effectively treats senile memory and mental decline. It is used to treat brain dysfunction psychiatric syndrome and mental disorders. It can improve the memory and learning abilities of patients with senile dementia or memory disorders. It is suitable for treating neural dysfunction, memory disorder and intelligence disorders caused by brain damage. It can also be used as a recovery treatment for neurosis, brain trauma, encephalitis, and other brain diseases. Oxiracetam’s greatest advantage is that it is very soluble in water, making it suitable for injection. Research shows that Oxiracetam has higher pharmacological activity and significant curative effects compared to Piracetam. | [Mechanisms of Action]
Oxiracetam’s mechanisms of action are similar to those of Piracetam. It promotes the binding of phosphorylcholine and phosphoethanolamine, increases the ratio of ATP/ADP in the brain, and increases the binding of protein with nucleic acids in the brain, thus improving the memory and learning ability of patients with senile dementia and memory disorder.
| [Pharmacokinetics]
After intake, most of the drug will not accumulate in the body and will be excreted through urine in its original form. It is well-absorbed and well-tolerated.
| [Clinical Research]
Animal trials showed that in all types of behavioral experiments, Oxiracetam can improve memory retention and learning ability, reduce brain shocks’ damage on memory, and prevent the learning abilities of rats suffering from spontaneous hypertensive cerebrovascular injury from decreasing. It can also increase acetylcholine circulation in rats’ skin and hippocampus, thus increasing affinity for choline uptake.
|
| Hazard Information | Back Directory | [Description]
Oxiracetam is a 4-hydroxy analog of piracetam, reportedly useful in relieving the
symptoms of cerebral insufficiency in the elderly. | [Chemical Properties]
Whie Solid | [Originator]
ISF (Italy) | [Uses]
Nootropic. Analog of Piracetam with psychostimulant activity. | [Definition]
ChEBI: Oxiracetam is an organooxygen compound and an organonitrogen compound. It is functionally related to an alpha-amino acid. | [Brand name]
Neuromet | [Biochem/physiol Actions]
Nootropic agent, improves learning and memory, and prevents impairment of cognitive functions. Its mechanism of action in not yet known, but it is suggested to modulate glutamatergic and cholinergic neurotransmission. Protein kinase C may be involved. | [storage]
Desiccate at -20°C | [Purification Methods]
This nootropic (Alzheimer) drug is purified by recrystallisation from MeOH or aqueous Me2CO and dried in vacuo. [NMR, IR: Pifferi & Pinza Farmaco Ed Sci 32 602 1977, Banfi et al. Farmaco Ed Sci 39 16 1984, Gouilaev & Senning Brain Research Rev 19 180 1994.] |
|
|